MMG Introduces Enhanced Education Platform for Clinical Trials
MMG announced an exclusive strategic partnership with online healthcare communications company MedRespond to introduce Custom Conversations
MMG, a global health communications company specializing in clinical trial patient recruitment and retention, announced an exclusive strategic partnership with online healthcare communications company MedRespond to introduce Custom Conversations, its new technological advancement in clinical trial patient education.
Custom Conversations uses video, natural language query capabilities, and the Internet to allow people exploring clinical trial options to have a more customized online learning interaction. An advanced synthetic interview technology developed by Carnegie Mellon University, allows people to also can ask questions in their own words, and then receive pre-recorded video responses which have been pre-approved by the study’s institutional review board or ethics committee.
According to MMG, pilot programs have shown clear boosts in enrollment rates compared to trials for which patients received only traditional study educational materials.
The Custom Conversations platform can be also be leveraged throughout the study education continuum – from first learning about a study, to pre-qualification and screening, and for the duration of the study, which can help to fortify retention. Sponsors receive insight into the anonymous activity data to get a view into patients’ and caregivers’ communication needs and mindsets, which can be used to refine recruitment and retention strategies and messaging.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
